Stock Analysis

Valbiotis Reports Full Year 2022 Earnings

Source: Shutterstock

Valbiotis (EPA:ALVAL) Full Year 2022 Results

Key Financial Results

  • Revenue: €2.81m (up by €2.52m from FY 2021).
  • Net loss: €12.3m (loss widened by 42% from FY 2021).
ENXTPA:ALVAL Earnings and Revenue History March 17th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Valbiotis Earnings Insights

Looking ahead, revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in France.

Performance of the French Biotechs industry.

The company's shares are up 11% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 4 warning signs for Valbiotis that you need to be mindful of.

Valuation is complex, but we're helping make it simple.

Find out whether Valbiotis is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis